Pituitary Pars intermedia Dysfunction – ein Update

Bis zu 25% der Pferde über 15 Jahre zeigen eines oder mehrere klinische Anzeichen einer Pituitary Pars intermedia Dysfunction. Damit ist sie die häufigste endokrinologische Erkrankung älterer Pferde und Tierärzte werden entsprechend oft damit konfrontiert.

Publication History

Article published online:
11 September 2023

• Literatur

• 1 McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clinics North Am Equine Pract 2011; 27 (01) 93-113
• 2 Schott HC. Pituitary pars intermedia dysfunction: Equine Cushingʼs disease. Vet Clinics North Am Equine Pract 2002; 18 (02) 237-270
• 3 McFarlane D, Dybdal N, Donaldson M. et al. Nitration and increased-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. J. Neuroendocrinol 2005; 17: 73-80
• 4 Fortin JS, Hetak AA, Duggan KE. et al. Equine pituitary pars intermedia dysfunction: A spontaneous model of synucleinopathy. Sci Rep 2021; 11: 16036
• 5 Miller MA, Pardo ID, Jackson LP. et al. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol 2008; 45: 26-38
• 6 Kritchevsky JE. Hypertrichosis Associated with Adenomas of the Pars Intermedia, MSD Manual Veterinary Manual 2022. Online (Letzter Zugriff: 29.06.2023): https://www.msdvetmanual.com/endocrine-system/the-pituitary-gland/hypertrichosis-associated-with-adenomas-of-the-pars-intermedia
• 7 van der Kolk JH, Kalsbeek HC, van Garderen E. et al. Equine pituitary neoplasia: A clinical report of 21 cases (1990–1992). Vet Rec 1993; 133: 594-597
• 8 McFarlane D, Donaldson MT, McDonnell SM. et al. Effects of season and sample handling on measurement of plasma α-melanocyte-stimulating hormone concentrations in horses and ponies. Am J Vet Res 2004; 65: 1463-1468
• 9 Banse HE, Whitehead AE, McFarlane D. et al. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy. Domest Anim Endocrinol 2021; 76: 106620
• 10 Ireland J, McGowan C. Epidemiology of pituitary pars intermedia dysfunction: A systematic literature review of clinical presentation, disease prevalence and risk factors. Vet J 2018; 235: 22-33
• 11 McFarlane D, Hill K, Anton J. Neutrophil function in healthy aged horses and horses with pituitary dysfunction. Vet Immunol Immunopathol 2015; 165: 99-106
• 12 Miller AB, Loynachan AT, Bush HM. et al. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses. Domest Anim Endocrinol 2021; 74: 106531
• 13 Keresztes M, Horváth T, Ocsovszki I. et al. ACTH- and cortisol-associated neutrophil modulation in coronary artery disease patients undergoing stent implantation. PLoS ONE 2013; 8: e71902
• 14 de Laat MA, McGowan C, Sillence M. et al. Equine laminitis: Induced by 48 h hyperinsulinaemia in Standardbred horses. Equine Vet J 2010; 42: 129-135
• 15 Equine Endocrinology Group. Pituitary Pars Intermedia Dysfunction 2021. Online (Letzter Zugriff: 29.06.2023): https://sites.tufts.edu/equineendogroup
• 16 McFarlane D, Beech J, Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest Anim Endocrinol 2006; 30: 276-288
• 17 Pease A, Schott H, Howey E. et al. Computed tomographic findings in the pituitary gland and brain of horses with pituitary pars intermedia dysfunction. J Vet Intern Med 2011; 25: 1144-1151
• 18 Durham A, McGowan C, Fey K. et al. Pituitary pars intermedia dysfunction: Diagnosis and treatment. Equine Vet Educ 2014; 26: 216-223
• 19 Rendle D, Doran G, Ireland J. et al. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction. Domest Anim Endocrinol 2019; 68: 135-141
• 20 Prascend Tablets Pergolide Mesylate. In: Proceedings of the Corrected Freedom of Information Summary, Boehringer Ingelheim Vetmedica, Ingelheim, Germany, 7 September 2011.